{"id":"NCT00320489","sponsor":"Eli Lilly and Company","briefTitle":"Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia","officialTitle":"A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2006-05-03","resultsPosted":"2010-10-22","lastUpdate":"2012-01-23"},"enrollment":524,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"olanzapine","otherNames":["LY170053","Zyprexa"]},{"type":"DRUG","name":"olanzapine pamoate depot","otherNames":[]}],"arms":[{"label":"Olanzapine Pamoate Depot","type":"EXPERIMENTAL"},{"label":"Olanzapine","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.","primaryOutcome":{"measure":"Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision)","timeFrame":"Baseline up to 104 weeks","effectByArm":[{"arm":"Olanzapine Pamoate Depot","deltaMin":644.5,"sd":null},{"arm":"Oral Olanzapine","deltaMin":677.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.612"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":49,"countries":["United States","Argentina","Brazil","Canada","France","Greece","Portugal","Puerto Rico","Romania","Slovakia","Spain","Taiwan"]},"refs":{"pmids":["24423017","22935168","20537130","20537128"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":264},"commonTop":["Weight increased","Insomnia","Somnolence","Anxiety","Headache"]}}